Advertisement
For patients with type 2 diabetes

Long-Acting Analog Insulin Doesn’t Up AMI Risk in T2DM

0
No significant difference in risk for long-acting analog, other basal insulin therapies
Strategies can be adopted for improving physician resilience and the ability to handle the challenges presented by patient care

Report Highlights Ways to Improve Physician Resilience

0
Recommendations include keeping a gratitude journal, enlisting peer support, learning new things
Use of patient navigators as inpatient care facilitators shortens hospital length of stay

Patient Navigators Tied to Shorter Hospital Stays

0
Use of patient navigators on general medical service didn't affect readmissions
Individuals who have many moles are at increased risk for melanoma skin cancer

Fewer Moles May Mean More Aggressive Melanoma

0
Patients may be less likely to get regular skin exams, advance warning about their risk
For hospitalized patients

Peripherally Inserted Central Catheters Up VTE Risk

0
In hospitalized patients, increased risk of upper- and lower-extremity deep vein thrombosis
Acetaminophen falsely increases continuous glucose monitor glucose values

Acetaminophen Falsely Elevates CGM Glucose Values

0
CGM glucose values increased versus blood glucose meter values in acetaminophen challenge
The United States should reconsider labeling of genetically modified food

U.S. Should Reconsider Labeling of Genetically Modified Food

0
Recommendation made in light of overreliance on herbicide glyphosate, a probable human carcinogen
Trials should be conducted to better establish the cardiovascular safety of testosterone therapy

Heart Safety of Testosterone Unclear for Older Men

0
Most men prescribed testosterone have age-related hypogonadism, for which treatment is not approved
A single nucleotide variant in the FTO obesity locus disrupts a conserved motif

Role of SNP Variant in FTO Explored in Obesity

0
Study identifies mechanistic basis for the strongest genetic association with obesity
Addyi (flibanserin) has been approved by the U.S. Food and Drug Administration as the first drug to treat generalized hypoactive sexual desire disorder among premenopausal women. The drug is for women who do not have an underlying physical or psychological cause for the disorder

FDA Approves Libido Pill for Women

0
Addyi to treat generalized hypoactive sexual desire disorder among premenopausal women